Incyte Gains 22.5% in Three Months, Beating Biotech Peers

Incyte Corporation (INCY) has returned 22.5% to shareholders over the past three months, doubling the 11% advance of the State Street SPDR S&P Biotech ETF (XBI) over the same period.

The Wilmington, Delaware-based biopharmaceutical company now trades just 4.3% below its 52-week high of $132.60, reached in July, according to Barchart data. Its market capitalization stands at approximately $25.3 billion, comfortably above the $10 billion threshold that defines large-cap stocks.

The longer-term record is more mixed. Over the past 52 weeks, Incyte's shares have climbed 49.8%, trailing XBI's 66.4% gain. Year-to-date, INCY is up 28.5% against the ETF's 32.8% rise. The recent three-month outperformance marks a shift in that dynamic.

Technicals Confirm the Trend

Incyte's chart supports the bullish case. Since June, the stock has traded above both its 50-day moving average of $122.72 and its 200-day moving average of $105.88, a pattern Barchart identifies as sustained upward momentum.

The rally reflects improving fundamentals and a stronger biotech backdrop, with investor interest in drug-development pipelines gaining traction. Incyte's growth outlook has strengthened alongside better performance across its commercial portfolio, according to the analysis.

Sales Acceleration Drives the Story

The numbers behind the rally are concrete. Incyte's Q2 FY2026 net sales increased 40.5% year over year to $1.5 billion. That figure includes a $246 million one-time benefit from Opzelura, the company's topical skin-treatment drug. Stripping out that benefit, sales still rose 17%.

Jakafi, Incyte's treatment for blood cancer, grew 6.9% year over year to $816.7 million. The company's hematology and oncology portfolio surged 69% over the same period.

Management responded to the momentum by raising its full-year FY2026 sales guidance to a range of $5.13 billion to $5.26 billion.

A Portfolio Built on Cancer and Blood Disorders

Incyte discovers, develops, and commercializes treatments for cancer, blood disorders, and immune-mediated diseases. Its marketed therapies include JAKAFI for blood cancer, ICLUSIG for leukemia, PEMAZYRE for bile-duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease.

Beyond the commercial portfolio, the company is advancing a clinical pipeline targeting additional cancers, myelofibrotic neoplasms and other myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

What to Watch

The gap between Incyte's short-term outperformance and its lag against XBI over 52 weeks leaves the stock at an inflection point. If the raised guidance holds and the pipeline delivers, the company could close the year closing the distance with the broader biotech benchmark — and defend its position near those July highs.